GlassScriptPhysician profile
Waled Bahaj
NPI 1316300601
$8,916.82
in general payments reported to CMS, 2019-2025
53 companies · $1,954 in 2025
The $1,954 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.60 · 2021: $26.42 · 2022: $1,546 · 2023: $2,135 · 2024: $3,242 · 2025: $1,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,838 · Education: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,838.07 |
| Education | $492.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $818.56 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Novartis Pharmaceuticals Corporation | $740.97 | 2023-2025 | |
| Incyte Corporation | $666.61 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $502.08 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $423.80 | 2023-2025 | Opdivo, Opdualag |
| Pfizer INC. | $386.90 | 2023-2025 | |
| Amgen INC. | $349.31 | 2022-2023 | Kyprolis, Lumakras, Blincyto |
| Janssen Biotech, INC. | $338.39 | 2023-2025 | Carvykti, Erleada, Rybrevant |
| Seagen INC. | $337.70 | 2022-2023 | Adcetris |
| Adaptive Biotechnologies Corporation | $310.52 | 2022-2025 | Clonoseq |
| Apellis Pharmaceuticals, INC. | $288.59 | 2022-2024 | Empaveli |
| Alexion Pharmaceuticals, INC. | $249.12 | 2021-2025 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $240.45 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Abbvie INC. | $231.04 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.80 | 2022-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $209.32 | 2022-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $206.43 | 2025 | Reblozyl, Opdivo |
| Gilead Sciences, INC. | $197.57 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $178.52 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Beigene USA, INC. | $177.50 | 2022-2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $142.64 | 2022-2025 | Tagrisso, Enhertu |
| Regeneron Healthcare Solutions, INC. | $134.65 | 2022-2025 | Libtayo |
| Adc Therapeutics America, INC. | $128.12 | 2022-2024 | |
| Mirati Therapeutics, INC. | $116.44 | 2023-2024 | Krazati |
| Emd Serono, INC. | $113.87 | 2022-2025 | |
| Eisai INC. | $109.88 | 2022-2025 | |
| Stemline Therapeutics INC. | $102.95 | 2023-2025 | Elzonris, Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.43 | 2025 | |
| Coherus Oncology, INC. | $82.69 | 2022-2025 | Loqtorzi, Udenyca |
| Puma Biotechnology, INC. | $75.26 | 2024-2025 | |
| Genentech USA, INC. | $74.99 | 2024-2025 | Polivy, Lunsumio, Tecentriq |
| Sobi, INC | $72.49 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $64.31 | 2024 | Cosela |
| Astellas Pharma US INC | $50.81 | 2025 | Cresemba |
| Genmab U.S., INC. | $47.56 | 2023-2025 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $40.73 | 2022-2023 | Tazverik |
| Glaxosmithkline, LLC. | $38.38 | 2023-2025 | Ojjaara, Blenrep |
| Blueprint Medicines Corporation | $38.13 | 2024-2025 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $37.11 | 2025 | Revuforj |
| Janssen Scientific Affairs, LLC | $33.33 | 2025 | Carvykti, Talvey, Tecvayli |
| Recordati_rare_diseases_inc. | $32.28 | 2025 | Sylvant |
| Sumitomo Pharma America, INC. | $21.60 | 2023 | Orgovyx |
| Pharmaessentia USA Corporation | $21.23 | 2025 | Besremi |
| Cti Biopharma Corp. | $19.25 | 2022 | |
| Acrotech Biopharma INC. | $19.04 | 2025 | Beleodaq |
| Kyowa Kirin, INC. | $18.66 | 2023 | Poteligeo |
| Sanofi-Aventis U.S. LLC | $18.49 | 2025 | |
| G1 Therapeutics, INC. | $17.46 | 2023 | Cosela |
| Geron Corporation | $16.67 | 2025 | Rytelo |
| Secura Bio, INC. | $16.55 | 2025 | Copiktra |
| Morphosys, US INC. | $14.87 | 2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $14.17 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waled Bahaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.